Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238381 | 0.81 | ACHE (0.67) | ACHEMKNK1MKNK2L3MBTL1LMNA | |
| SCHEMBL22399206 | 0.80 | ACHE (0.68) | ACHEMKNK1MKNK2L3MBTL1LMNA | |
| SCHEMBL659349 | 0.75 | ACHE (0.64) | ACHEMKNK1MKNK2LMNAADORA2A | |
| SCHEMBL29399366 | 0.75 | ACHE (0.54) | ACHEMKNK1MKNK2L3MBTL1LMNA | |
| SCHEMBL25819849 | 0.74 | ACHE (0.49) | ACHEMKNK1MKNK2LMNAMAPKAPK2 | |
| SCHEMBL28309802 | 0.74 | ACHE (0.49) | ACHEMKNK1MKNK2LMNAMAPKAPK2 | |
| SCHEMBL30338024 | 0.74 | ACHE (0.54) | ACHEMKNK1MKNK2L3MBTL1TLR8 | |
| SCHEMBL30961721 | 0.73 | ACHE (0.51) | ACHEMKNK1MKNK2LMNA | |
| SCHEMBL12862846 | 0.72 | ACHE (0.47) | ACHEMKNK1MKNK2LMNAMAPKAPK2 | |
| SCHEMBL566139 | 0.72 | ACHE (0.50) | ACHEMKNK1MKNK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ACHE 4444/4885NNMT 4490/4885MKNK1 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.